Phase I Study of Proteolysis-Targeting Chimera Degrader ARV-110 in Metastatic Castration-Resistant Prostate Cancer

May 29-31, 2020; Online at
ARV-110, a proteolysis-targeting chimera, shows promising clinical activity in heavily pretreated mCRPC patients who have received at least 1 second-generation AR therapy.
Format: Microsoft PowerPoint (.ppt)
File Size: 234 KB
Released: June 8, 2020


Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

Supported by educational grants from
Bayer HealthCare Pharmaceuticals Inc.
Bristol-Myers Squibb
Pfizer and EMD Serono, Inc.

Related Content

From Clinical Care Options (CCO), video featuring expert presentations on the role of PARP inhibition in the treatment of prostate cancer

Celestia Higano Headshot Celestia S. Higano, MD, FACP
Program Director
Charles J. Ryan, MD
Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: August 10, 2020 Expired: August 9, 2021

Gain key clinical insights fast, with this short slideset from CCO on biomarkers for imuno-onolcogy approaches across solid tumors

Jamie E. Chaft, MD John L. Marshall, MD Scot Niglio, MD Released: July 15, 2020

Gain key clinical insights fast, with this short slideset from CCO on PARP inhibitor therapy for the treatment of patients with DNA repair–deficient prostate cancer.

Celestia Higano Headshot Celestia S. Higano, MD, FACP Charles J. Ryan, MD Released: July 14, 2020

In this commentary from Clinical Care Options (CCO), Alexander Drilon, MD, discusses best practices in the use of TRK inhibitor therapy

person default Alexander Drilon, MD Released: July 10, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the,, and Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?